Introduction
============

Purulent meningitis (PM), caused by pyogenic bacteria, is common in children aged ≤5 years ([@b1-etm-0-0-8769]). The incidence of PM in children is increasing, with the number of new cases of infantile PM globally exceeding 300,000 as of 2015([@b2-etm-0-0-8769]). Additionally, it was previously reported that the incidence of PM is exhibiting major geographical differences, with higher rates of incidence observed in developing countries ([@b3-etm-0-0-8769]). Infants are particularly vulnerable to a variety of PM-causing pyogenic bacterial infections, the most common species being *Neisseria meningitidis.*, *Streptococcus pneumoniae* and *Haemophilus influenzae* ([@b4-etm-0-0-8769]). Since acute infant PM is severe and harmful, missing the optimal treatment time directly endangers the life of the patients ([@b5-etm-0-0-8769]); if not treated on time, the mortality rate associated with this disease can reach 50-70% ([@b6-etm-0-0-8769]).

Accumulating evidence has demonstrated that the optimal treatment strategy for PM is antibiotic therapy ([@b7-etm-0-0-8769]). However, in recent years, novel pharmacological agents for the effective treatment of PM such as ceftriaxone have been developed with advancing technology ([@b8-etm-0-0-8769]). The antibacterial spectrum of ceftriaxone sodium is comparable to that of cefotaxime sodium, which it has potent effects against *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, *Serratia*, *Meningococcus* and *Neisseria gonorrhoeae* ([@b9-etm-0-0-8769]). Although it has been demonstrated in a number of previous studies to be highly effective for the treatment of infant PM ([@b10-etm-0-0-8769]), the efficacy of ceftriaxone sodium in infantile PM is deteriorating due to a surge of bacterial resistance in the population ([@b13-etm-0-0-8769]). Dexamethasone is a synthetic corticosteroid which exhibits anti-inflammatory properties and that is considered safe in pregnant women and newborns ([@b14-etm-0-0-8769],[@b15-etm-0-0-8769]). Previous studies have shown that the additive use of dexamethasone can greatly enhance the efficacy of antibiotics ([@b16-etm-0-0-8769],[@b17-etm-0-0-8769]). At present, limited information exist on the efficacy of ceftriaxone sodium combined with dexamethasone on the treatment of infant PM. The present study retrospectively analyzed the role of ceftriaxone sodium combined with dexamethasone for the treatment of infant PM at the Department of Pediatrics, Yongchuan Hospital of Chongqing Medical University (Chongqing, China) and its associated effects on brain-derived neurotrophic factor (BDNF) levels. The study provides an effective reference and guidance for future clinical management of PM.

Patients and methods
====================

### Patients

A retrospective analysis was performed on 177 children (sex, 114 males and 63 females; age range, between 5 months and 6 years; mean age, 3.27±1.42 years) who were admitted to Yongchuan Hospital of Chongqing Medical University (Chongqing, China) between January 2015 and February 2016. The present study was approved by the Ethics Committee of Yongchuan Hospital of Chongqing Medical University (Chongqing, China) and informed consent was obtained from the parents of all subjects.

The inclusion criteria were: i) Age of patient \<8 years; ii) Early symptoms of meningitis, including nausea and vomiting; fever; headache and a stiff neck; muscle pain; sensitivity to light; confusion; cold hands or feet and mottled skin; in some cases, subjects had a rash that did not fade under pressure. Later symptoms included seizures and coma. iii) diagnosed with PM with severity evaluated following cerebrospinal fluid (CSF) and CT examination at the hospital using the diagnostic criteria of the 2015 PM Diagnostic Guidelines ([@b14-etm-0-0-8769]); iv) was receiving follow-up treatment in our hospital after diagnosis; v) cooperation with hospital staff; and vi) having complete set of medical records.

The exclusion criteria were: i) Patients with cancer, diseases of the immune system, blood or severe organ disorders, hepatocellular failure or renal failure, other infectious diseases and drug allergies; ii) patients who received medical treatments other than prescribed drugs from our hospital following diagnosis; and iii) patients who were transferred from other hospitals.

### Methods

Following explanation of the mechanism of action and effects of ceftriaxone sodium and dexamethasone, the families of the respective patients selected the treatment regimens independently. Of the 177 patients enrolled into the present study, 92 were treated with ceftriaxone sodium combined with dexamethasone, which served as the combination group; the other 85 patients who received ceftriaxone sodium treatment only served as the monotherapy group. The treatment regimens performed in the present study were determined in accordance with the bacterial species found. For any cases of unidentified pathogenic bacterial suppurative meningitis, third-generation ceftriaxone or cefotaxime was used as the first choice of treatment, whilst for pneumococcal disease, high-dose penicillin was used. For those who were resistant to penicillin, ceftriaxone was considered in addition to vancomycin. For meningococcal infection, penicillin was preferred, whereas those who were penicillin-resistant were treated with cefotaxime or ceftriaxone. Ceftazidime was used for meningitis caused by *Pseudomonas aeruginosa*, whilst ceftriaxone, cefotaxime or ceftazidime was used for other forms of meningitis caused by gram-negative bacilli.

The monotherapy group was administered \~70-90 mg/kg ceftriaxone sodium once daily (Southwest Pharmaceutical Co., Ltd.), whereas the combination group was administered additively with 0.3 mg/kg dexamethasone once daily (Guizhou Tiandi Pharmaceutical Co., Ltd.). Both groups of treatment regimens lasted for two weeks, which would be stopped immediately if any patient developed an adverse reaction. The recovery of a set of PM indicators to normal healthy levels was considered as the completion of treatment. CSF samples (3 ml) were obtained within three days prior to treatment (T1), at one week after treatment (T2) and two weeks after treatment (T3) for further analysis. After centrifugation at 1,500 x g for 5 min at 4˚C, the supernatant was taken for subsequent testing.

### Outcome indicators

Clinical data from the two groups of children, including age, course of disease, weight, red blood cell (RBC) count, white blood cell (WBC) count, platelet count, sex, place of residence and first onset of symptoms were compared. The rehabilitation indicators measured were time taken for the recovery of body temperature and WBC counts in both the peripheral blood (PB) and CSF returning to normal, healthy levels. The CSF biochemical indicators included WBC count, concentration of protein and sugar in the CSF and BDNF levels. BDNF levels in the CSF were analyzed using an ELISA kit (Shanghai Yubo Biological Technology Co., Ltd.; cat. no. KT11531), whilst the biochemical parameters in CSF were determined using an automatic biochemical analyzer (AU5800; Beckman Coulter, Inc.).

### Effective rate

The effective treatment rates were determined using the evaluation criteria referred to as the 2015 PM Rehabilitation Guidelines ([@b14-etm-0-0-8769]). Clinical symptoms and normal CSF examination findings were defined as 'effective'; normalized clinical symptoms and CSF examination findings or results indicating significant improvement were defined 'improved'; and clinical symptoms and CSF examination findings revealing uniformity or even deterioration were defined as 'ineffective.' The effective treatment rate was calculated using the following formula: \[('Effective' + 'Improved')/total number of cases\] x100%. The incidence of adverse reactions was using the following formula: (Number of patients with adverse reactions during treatment/total number of cases) x100%.

### Statistical analysis

The data were analyzed using SPSS version 24.0 (IBM Corp.). Categorical variables and effective treatment rates between the two groups were compared using the Chi-square test. Continuous variables, including the recovery time of body temperature and WBC counts, were presented as the mean ± standard deviation and compared between the two groups using Student\'s t-test. Multiple time points were compared using repeated measures ANOVA followed by Bonferroni test. P\<0.05 was considered to indicate a statistically significant difference. The experiments were repeated 3 times.

Results
=======

### General data and rehabilitation outcomes

There were no significant differences in age, gender, body weight, location of residence, total bilirubin levels, BUN, number of siblings, family medical history, course of disease, species of pathogens, severity of disease, red blood cell (RBC), WBC and platelet (PLT) counts in routine blood examinations between the two groups, suggesting that the two groups were comparable prior to treatment ([Table I](#tI-etm-0-0-8769){ref-type="table"}).

The recovery time of body temperature in the combination group was 2.87±0.74 days, which was significantly shorter compared with that in the monotherapy group (3.67±0.94 days; P\<0.05; [Fig. 1](#f1-etm-0-0-8769){ref-type="fig"}). The recovery time of the PB WBC count in the combination group was 5.57±2.07, which was significantly shorter compared with that in the monotherapy group (8.04±1.68 days; P\<0.05; [Fig. 2](#f2-etm-0-0-8769){ref-type="fig"}). The recovery time for CSF WBC count to normal level in the combination group was 14.14±1.24 days, which was also significantly shorter compared with that in the monotherapy group (17.84±2.07 days; P\<0.05; [Fig. 3](#f3-etm-0-0-8769){ref-type="fig"}).

### Comparison of the CSF biochemical parameters

No significant differences were observed in the WBC count ([Fig. 4](#f4-etm-0-0-8769){ref-type="fig"}), CSF protein ([Fig. 5](#f5-etm-0-0-8769){ref-type="fig"}) and sugar concentrations ([Fig. 6](#f6-etm-0-0-8769){ref-type="fig"}) between the combination and the monotherapy groups at T1. At T2, the WBC count (62.87±10.54x10^6^/l) and CSF protein concentration (0.61±0.10 g/l) in the combination group were significantly lower (both P\<0.05) compared with those in the monotherapy group (WBC count, 75.24±12.84x10^6^/l; CSF protein concentration, 0.81±0.14 g/l). The CSF sugar concentration in the combination group was 2.57±0.61 mmol/l, which was significantly higher compared with that in the monotherapy group (1.47±0.54 mmol/l; P\<0.05) at T2. At T3, the WBC count and CSF protein concentration in the combination group were 34.71±8.68x10^6^/l and 0.37±0.08 g/l, respectively, both of which were also significantly lower (both P\<0.05) compared with those in the monotherapy group (WBC count, 51.63±10.54x10^6^/l; CSF protein concentration, 0.59±0.11 g/l). The CSF sugar concentration in the combination group was 3.62±0.95 mmol/l, which was also significantly higher compared with that in the monotherapy group (2.31±0.70 mmol/l; P\<0.05).

The WBC count and CSF protein concentrations in both groups were lower at T2 compared with those at T1 (P\<0.05), which decreased further at T3 (P\<0.05). By contrast, the CSF sugar concentration of the combination group increased at T2 compared with T1 (P\<0.050), which increased further at T3 (P\<0.05). No significant differences in the CSF sugar concentration could be identified between T1 and T2 in the monotherapy group, although it was higher at T3 compared with T1 (P\<0.05; [Figs. 4-6](#f4-etm-0-0-8769 f5-etm-0-0-8769 f6-etm-0-0-8769){ref-type="fig"}).

### Comparison of effective treatment rates and adverse reactions

The effective treatment rate for the combination group was calculated to be 94.57%, which was significantly higher compared with that of the monotherapy group (76.47%; P=0.006; [Table II](#tII-etm-0-0-8769){ref-type="table"}). In the combination group, the patients were primarily 'effective' to the treatment, accounting for 61.96%, whilst in the monotherapy group, a slight majority of the patients were categorized as 'improved' (38.82%). The incidence of adverse reactions in the combination group was calculated to be 5.43%, which was not significantly different compared with the monotherapy group ([Table III](#tIII-etm-0-0-8769){ref-type="table"}).

### Comparison of BDNF levels

There was no significant difference in the BDNF levels between the two groups at T1 ([Fig. 7](#f7-etm-0-0-8769){ref-type="fig"}). The BDNF levels in the combination group at T2 was 12.84±6.24, which was significantly higher compared with that in the monotherapy group (8.67±3.65; P\<0.05; [Fig. 7](#f7-etm-0-0-8769){ref-type="fig"}). The BDNF levels in the combination group at T3 was 27.52±5.61, which was also significantly higher compared with that in the monotherapy group (16.84±5.99; P\<0.05; [Fig. 7](#f7-etm-0-0-8769){ref-type="fig"}).

The BDNF levels in both groups were significantly increased at T2 (P\<0.05) which increased further at T3 (P\<0.05; [Fig. 7](#f7-etm-0-0-8769){ref-type="fig"}).

Discussion
==========

PM is an infectious disease caused by purulent bacterial infection in the central nervous system (CNS). Specifically, toxins produced by the bacteria can induce aberrant inflammatory responses in the arachnoid and pia mater. If not treated immediately, the bacterial toxins can spread to the brain parenchyma and spinal cord, at which point more intensive treatments would be required with a guarded prognosis ([@b18-etm-0-0-8769]). The main pathogens responsible for infant PM are gram-negative bacteria and *Staphylococcus aureus* ([@b19-etm-0-0-8769]). PM is frequently accompanied with fibrin exudation and neutrophil infiltration, resulting in susceptibility to inflammatory small vessel embolism, focal cerebral infarction and encephalorrhagia ([@b20-etm-0-0-8769]). On clinical suspicion of PM, an empirical antibacterial therapeutic strategy is first adopted, where targeted antibiotic treatment is initiated as soon as the presence of the pathogen is confirmed ([@b21-etm-0-0-8769]).

Among the antibacterial pharmacological agents currently applied for PM, ceftriaxone sodium is the most frequently used. Mechanistically, ceftriaxone sodium operates by increasing the expression of intracellular glutamate transporters to reduce the levels of excitatory glutamate and enhance neuroprotection, reducing the risk of brain tissue damage ([@b22-etm-0-0-8769]). However, with the rise in drug-resistant bacterial strains, the use of ceftriaxone alone has not achieved desirable outcomes for the treatment of PM. In such cases, administration of dexamethasone, a commonly used glucocorticoid, is applied. In addition to the suppression of inflammation by mainly inhibiting macrophage activity, dexamethasone has also been previously demonstrated to reduce intracranial pressure and cerebral edema ([@b23-etm-0-0-8769]).

BDNF is a vital neurotrophic factor in CNS that serves a role in promoting neuronal survival and differentiation in the human body ([@b24-etm-0-0-8769]). For the treatment of PM, BDNF application can significantly reduce neuronal damage in the hippocampus, which may accelerate rehabilitation and improve prognosis. However, insufficient studies regarding the association between PM and BDNF exist. By comparing the efficacy of ceftriaxone sodium combined with dexamethasone to ceftriaxone sodium alone in patients with PM and monitoring changes in BDNF levels, the present study demonstrated a potential clinical role of ceftriaxone sodium combined with dexamethasone for infant PM treatment.

The results from the present study indicated that the effective treatment rate of the combination group was superior to that of the monotherapy group. The recovery time of body temperature, PB and CF WBC counts in the combination group was shorter compared with that of the monotherapy group, suggesting that ceftriaxone sodium combined with dexamethasone in PM was more effective compared with ceftriaxone alone. It could be hypothesized that these observations may be due to the anti-inflammatory properties of dexamethasone or the expansion of the ceftriaxone antibacterial spectrum. The use of ceftriaxone sodium alone has poor antibacterial effect and is likely to cause resistance in children. In children with PM, the metabolic function of central nervous system is abnormal due to the influence of bacterial toxins, which has an impact on glucose transporters and blood circulation fluidity ([@b25-etm-0-0-8769]).

There was no significant difference in the incidence of adverse reactions between the two treatment groups, suggesting that both therapeutic strategies are safe and worthy of clinical promotion. Some bacteria are able to convert glucose in the CSF to lactic acid ([@b26-etm-0-0-8769]), where the resultant inflammatory response can increase the level of antibodies in the CSF of patients with PM ([@b27-etm-0-0-8769]). Compared with the monotherapy group, CSF sugar concentrations were higher in the combination group, whilst the CSF protein concentrations were lower, suggesting that ceftriaxone sodium combined with dexamethasone was more effective in improving CSF function and CNS metabolism.

Dexamethasone inhibits the release of chemokines by reducing the stimulation of the inflammatory cells such as monocytes ([@b28-etm-0-0-8769]). As a result, damage to the neurovascular system is greatly reduced. In addition, dexamethasone contributed to the stabilization of the vascular endothelial structure and was of great significance to the protection of neurons and blood vessels ([@b29-etm-0-0-8769]). This was speculated to be a reason for the higher BDNF levels observed in the combination group compared with the monotherapy group in the present study. Previous studies have demonstrated that BDNF can regulate the expression of cortical neurons and hippocampal neurons through the MARK/ERK pathway ([@b30-etm-0-0-8769],[@b31-etm-0-0-8769]). Although it could be speculated that dexamethasone inhibited the MAPK/ERK pathway, further research is required to explore the intracellular mechanism of BDNF action.

Small sample size was a limitation of this study. Further research and discussion are needed to clarify the mechanism of the effects of the combination of ceftriaxone sodium and dexamethasone on BDNF levels in infant PM. A longer follow-up of patients should be performed in a future study.

In conclusion, the effects of ceftriaxone combined with dexamethasone for the treatment of infant PM was found to be superior compared with ceftriaxone alone. In addition, ceftriaxone combined with dexamethasone improved the effective treatment rate and rehabilitation of patients with PM and also improved the BDNF levels in patients.
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![CSF WBC counts between the combination and monotherapy groups during treatment as measured at three different time points. At both T2 and T3, the CSF WBC counts in the monotherapy group were significantly higher compared with those in the combination group. In both groups, the WBC count was lower at T3 compared with T2, which were in turn lower compared with T1. ^\*^P\<0.05 vs. combination; ^\#^P\<0.05 vs. corresponding value at T1 and ^&^P\<0.05 vs. corresponding value at T2. WBC, white blood cell; CSF, cerebrospinal fluid; T1, before treatment; T2, one week after treatment; T3, two weeks after treatment.](etm-20-02-0945-g03){#f4-etm-0-0-8769}
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![CSF sugar concentrations between the combination and monotherapy groups during treatment as measured at three different time points. At both T2 and T3, CSF sugar concentrations were significantly lower in the monotherapy group compared with the combination group. In the combination group, the CSF sugar concentrations were significantly higher at T3 compared with at T2, which were in turn higher compared with those at T1. ^\*^P\<0.05 vs. combination; ^\#^P\<0.05 vs. corresponding value at T1 and ^&^P\<0.05 vs. corresponding value at T2. CSF, cerebrospinal fluid; T1, before treatment; T2, one week after treatment; T3, two weeks after treatment.](etm-20-02-0945-g05){#f6-etm-0-0-8769}

![Comparison of changes in BDNF levels between the combination and monotherapy groups during treatment as measured at three different time points. BDNF levels in the monotherapy group was significantly lower compared with that in the combination group at T2 and T3. In both groups, BDNF levels were higher at T3 compared with T2, which were in turn higher compared with T1. ^\*^P\<0.05 vs. combination; ^\#^P\<0.05 vs. corresponding value at T1 and ^&^P\<0.05 vs. corresponding value at T2. BDNF, brain-derived neurotrophic factor; T1, before treatment; T2, one week after treatment; T3, two weeks after treatment.](etm-20-02-0945-g06){#f7-etm-0-0-8769}

###### 

General characteristics of patients.

  Characteristic                   Combination (n=92)   Monotherapy (n=85)   X^2^ or t   P-value
  -------------------------------- -------------------- -------------------- ----------- ---------
  Age                              3.42±1.67            3.18±1.84            0.91        0.36
  Course of disease (days)         5.23±1.04            5.51±1.22            1.647       0.1
  Body weight (kg)                 16.63±5.27           17.52±6.04           1.047       0.3
  RBC (x10^12^/l)                  4.12±0.84            4.09±1.15            0.199       0.84
  WBC (x10^9^/l)                   47.24±7.68           45.81±8.54           1.173       0.24
  PLT (x10^9^/l)                   247.52±24.16         241.34±26.54         1.622       0.11
  Total bilirubin at T1 (µmol/l)   16.72±2.51           17.21±2.66           1.261       0.21
  Total bilirubin at T3 (µmol/l)   15.62±2.16           15.16±2.38           1.348       0.18
  BUN at T1                        5.65±2.06            5.87±2.05            0.712       0.48
  BUN at T3                        5.12±1.04            5.25±1.27            0.747       0.46
  Sex                                                                                     
       Male                        62 (67.39)           52 (61.18)                        
       Female                      30 (32.61)           33 (38.82)                        
  Place of residence                                                         0.689       0.41
       Town                        69 (75.00)           59 (69.41)                        
       Rural                       23 (25.00)           26 (30.59)                        
  Only Child                                                                 0.431       0.51
       Yes                         50 (54.35)           42 (49.41)                        
       No                          42 (45.65)           43 (50.59)                        
  First onset                                                                1.221       0.27
       Yes                         81 (88.04)           79 (92.94)                        
       No                          11 (11.96)           6 (7.06)                          
  Pathogen species                                                           0.701       0.7
       *Meningococcus*             38 (41.30)           32 (37.65)                        
       Gram-negative bacilli       30 (32.61)           26 (30.59)                        
       *Pneumococcus*              24 (26.09)           27 (31.76)                        
  Family medical history                                                     0.255       0.61
       Yes                         12 (13.04)           9 (10.59)                         
       No                          80 (86.96)           76 (89.41)                        
  Severity of disease                                                        0.099       0.95
       Ordinary type               47 (51.09)           44 (51.76)                        
       Sudden                      19 (20.65)           16 (18.82)                        
       Light                       26 (28.26)           25 (29.41)                        

Categorical variables, are presented as n, (%). Continuous variables are presented as the mean ± SD. RBC, red blood cell; WBC, white blood cell; PLT, platelets; BUN, blood urea nitrogen.

###### 

Comparison of treatment effectiveness.

  Outcome                        Combination group (n=92)   Monotherapy group (n=85)   X^2^     P-value
  ------------------------------ -------------------------- -------------------------- -------- ---------
  Effective \[n (%)\]            57 (61.96)                 32 (37.65)                           
  Improved \[n (%)\]             30 (32.61)                 33 (38.82)                           
  Ineffective \[n (%)\]          5 (5.43)                   20 (23.53)                           
  Effective treatment rate (%)   94.57%                     76.47%                     11.930   0.006

###### 

Comparison of incidence of adverse reactions.

  Adverse reaction            Combination group (n=92)   Monotherapy group (n=85)   X^2^    P-value
  --------------------------- -------------------------- -------------------------- ------- ---------
  Rash \[n (%)\]              0 (0.00)                   1 (1.18)                   1.089   0.297
  Jaundice \[n (%)\]          2 (2.17)                   2 (2.35)                   0.006   0.936
  Flatulence \[n (%)\]        1 (1.09)                   0 (0.00)                   0.929   0.335
  Diarrhea \[n (%)\]          3 (3.26)                   4 (4.71)                   0.243   0.622
  Adverse reaction rate (%)   5.43%                      8.24%                      0.548   0.459
